[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100606792":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":35,"centralContacts":40,"locations":45,"responsibleParty":62,"collaborators":26,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":67,"sex":73,"minAge":74,"maxAge":26,"enrollmentInfo":75,"targetDuration":26,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":26,"overallStatus":48,"whyStopped":26,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"RenJi Hospital","OTHER",[8,16],{"label":9,"type":10,"description":11,"interventionNames":12},"QL1706","EXPERIMENTAL","QL1706 + CDK4\u002F6 inhibitor + fulvestrant\u002Fletrozole",[13,14,15],"Drug: QL1706","Drug: CDK4\u002F6 inhibitor","Drug: Fulvestrant",{"label":17,"type":18,"description":19,"interventionNames":20},"control","ACTIVE_COMPARATOR","CDK4\u002F6 inhibitor + fulvestrant\u002Fletrozole",[14,15],[22,27,31],{"type":23,"name":9,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","QL1706 is a single bifunctional MabPair product consisting of two engineered monoclonal antibodies (anti-PD-1 and anti-CTLA-4).",[9],null,{"type":23,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"CDK4\u002F6 inhibitor","palbociclib OR ribociclib OR abemaciclib OR dalpiciclib",[9,17],{"type":23,"name":32,"description":33,"armGroupLabels":34,"otherNames":26},"Fulvestrant","SERD",[9,17],[36],{"name":37,"affiliation":38,"role":39},"Wenjin Yin, M.D.","Renji Hospital,School of Medicine, Shanghai Jiaotong University","PRINCIPAL_INVESTIGATOR",[41],{"name":37,"role":42,"phone":43,"phoneExt":26,"email":44},"CONTACT","86(21)68385569","yinwenjin@renji.com",[46],{"facility":47,"status":48,"city":49,"state":26,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"Renji Hospital, School of Medicine, Shanghai Jiaotong University","RECRUITING","Shanghai","200127","China","CN",{"type":54,"coordinates":55},"Point",[56,57],121.45806,31.22222,{"lat":57,"lon":56},[60],{"name":61,"role":42,"phone":43,"phoneExt":26,"email":44},"Wenjin Yin",{"type":63,"investigatorFullName":61,"investigatorTitle":64,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"SPONSOR_INVESTIGATOR","Deputy Chief of Breast Surgery Department","100606792","phase-2-iparomlimab-and-tuvonralimab-ql1706-in-patients-with-hr-positive-her2-negative-advanced-breast-cancer-100606792",false,"NCT07180160","Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer","Iparomlimab and Tuvonralimab (QL1706) in Patients With Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer: a Prospective, Randomised, Controlled, Multicentre Clinical Trial","ITHRAN","Inclusion Criteria:\n\n* Female, age≥18 years old\n* Expected survival ≥12 weeks\n* ECOG 0-1\n* Pathologically confirmed recurrent or metastatic breast cancer not amenable to curative surgery\n* ER and\u002For PR positive, HER2 negative\n* At least one measurable lesion or bone-only disease (osteolytic or mixed) according to RECIST v1.1\n* Previously treated with ≤2 lines chemotherapy for advanced disease; previously treated with ≤2 CDK4\u002F6 inhibitors\n* Adequate organ function\n\nExclusion Criteria:\n\n* During pregnancy and lactation\n* Patients with central nervous system metastasis","FEMALE","18 Years",{"count":76,"type":77},123,"ESTIMATED","INTERVENTIONAL",[80],"PHASE2","This is a prospective, randomised, controlled, multicentre study to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab (QL1706) in patients with hormone receptor-positive\u002Fhuman epidermal growth factor receptor 2-negative advanced breast cancer.",[83],"Advanced Breast Cancer","2025-11-16",{"date":86,"type":87},"2025-11-18","ACTUAL",{"date":89,"type":87},"2025-09-25",{"date":91,"type":77},"2028-03",{"name":61,"class":6},1]